Table 2 Preferences for PA types and places for practice (% patients reporting the preference)
Cancer type | Country, no. of participants, treatment stage | Study design | PA types | Places for PA practice | Reference | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(A) Walking, (B) Cycling, (C) Swimming, (D) Jogging, (E) Dancing, (F) Gardening, (G) Gymnastics, (H) Strength training, (I) Ball sports, (J) Yoga, (K) Resistance weight training, and (L) Stretching | (A) Home, (B) Outdoors/park, (C) Fitness center, and (D) Cancer center/hospital | ||||||||||||||||||
(A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (A) | (B) | (C) | (D) | ||||
Brain | Canada, 31, on ttt | CS | + (45) | + (6) | + (58) | + (16) | [87] | ||||||||||||
US, 106, mixed | CS | + (51) | + (44) | + (26) | + (9) | + (6) | [88] | ||||||||||||
Breast | Canada, 524, post-ttt | CS | + (51) | + (27) | + (36) | + (36) | + (32) | + (51) | + (5) | [89] | |||||||||
Canada, 12, mixed | FG | + | + | + | + | [50] | |||||||||||||
US, 60, post-ttt | QI | + (52) | + (37) | + (23) | + (80) | + (52) | [54] | ||||||||||||
US, 23, during ttt | CS | +(100) | + (74) | + (61) | + (4) | + (35) | + (52) | + (48) | + (30) | + (22) | [55] | ||||||||
US, 160, during ttt | CS | + (59) | + (23) | + (6) | + (14) | + (14) | + (22) | [90] | |||||||||||
Colo-rectal | Australia,10, post-ttt | QI | + | + | + | + | + | + | [56] | ||||||||||
Canada, 600, mixed | CS | + (49) | + (4) | + (8) | + (56) | + (40) | + (28) | + (10) | [91] | ||||||||||
Netherlands, 15, mixed | QI | + | + | + | + | + | [92] | ||||||||||||
Endometrial | UK, 16, post-ttt | QI | + | [60] | |||||||||||||||
Gynecologic | Canada, 239 patients | MM | + (81) | [44] | |||||||||||||||
Lung | Australia, 7, post-ttt | FG | + | + | + | + | + | [63] | |||||||||||
US, 43, pre-ttt | CS | + (49) | + (14) | +(23) | [65] | ||||||||||||||
US, 175, post-ttt | CS | + (26) | + (6) | + (12) | + (6) | + (18) | +(10) | [38] | |||||||||||
Multiple myeloma | Australia, 24, post-ttt | QI | + | + | + | + | + | + | + | + | [66] | ||||||||
Ovarian | Canada, 359, mixed | CS | + (63) | + (3) | + (4) | + (4) | + (49) | + (21) | + (7) | [45] | |||||||||
Prostate | Australia, 18, post-ttt | QI | + | + | + | + | + | + | [68] | ||||||||||
Testicular | Norway, 9, mixed | QI | + (67) | + (11) | [93] | ||||||||||||||
Variousa | Australia, 92, during ttt | CS | + (68) | + (4) | + (6) | + (5) | + (9) | + (53) | + (15) | [94] | |||||||||
Canada, 66, mixed | CS | + (60) | +(32) | [72] | |||||||||||||||
England, 59, mixed | CS | + (52) | + (18) | +(73) | + (18) | + (17) | |||||||||||||
Germany, 155, mixed | CS | + (45) | + (45) | + (45) | + (13) | + (20) | + (13) | [95] | |||||||||||
Ireland, 41, mixed | FG | + (15) | + (66) | + (3) | + (68) | [77] | |||||||||||||
Italy, 392, mixed | CS | + (21) | + (27) | + (12) | [46] | ||||||||||||||
UK, 26, mixed stages | FG | + | [84] | ||||||||||||||||
UK, 456 patients | CS | + (73) | + (31) | + (34) | + (26) | + (31) | + (14) | + (23) | +(16) | [43] | |||||||||
US, 20, during ttt | QI | + (80) | [85] | ||||||||||||||||
US, 162, mixed | CS | + (73) | + (64) | + (58) | + (36) | + (35) | + (31) | + (91) | + (58) | + (64) | [96] | ||||||||